President Donald Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate research and regulatory review of psychedelic drugs as potential treatments for serious mental illness, in a signing ceremony attended by podcaster Joe Rogan, Health Secretary Robert F. Kennedy Jr. and veterans who credit psychedelic experiences with changing the course of their lives. The order, titled Accelerating Medical Treatments for Serious Mental Illness, does not legalise psychedelics, does not approve any psychedelic drug, and does not make any such treatment generally available. What it does is use the machinery of the executive branch, including priority review vouchers, research funding and a Right to Try pathway, to try to shorten the distance between promising early evidence and a treatment that has been proved safe and effective through the normal regulatory process.
The ceremony itself became part of the story, because of how the order came about. Rogan, who endorsed Trump in the 2024 election and commands one of the largest podcast audiences in the country, has said he sent the president information about ibogaine, a psychoactive compound derived from an African plant, and received an immediate, enthusiastic reply. Trump, at the signing, credited calls from several people, including Rogan, urging action on veteran suicide and severe mental illness. Rogan’s account, that Trump replied in substance, “Sounds great. Do you want FDA approval? Let’s do it,” has been widely quoted, but Trump also said he consulted Kennedy and other administration officials before acting, and the order itself is a formal policy document, not a text-message approval. The distinction matters for readers trying to judge what actually changed on April 18, as opposed to what was said in the room.
The order’s stated premise is stark. It notes that more than 14 million American adults live with a serious mental illness, defined as a diagnosable mental, behavioural or emotional disorder that substantially interferes with life and functioning, and that about 8 million are on prescription medication for such conditions. It cites a rise in suicide rates over two decades, and it emphasises that veterans suffer disproportionately, with more than 6,000 veteran suicides a year for over 20 years and a veteran suicide rate described as more than twice that of the non-veteran adult population. Those figures frame the administration’s argument: existing treatments help many people, but a substantial group relapses or does not fully respond, and the search for new approaches is urgent. Critics do not dispute that mental illness and veteran suicide are serious problems; they dispute whether psychedelics, and ibogaine in particular, have been proved to be the answer, and whether accelerating review risks lowering the evidentiary bar.
What the Trump psychedelic executive order actually does
The order’s operative provisions are specific, and they are worth setting out in plain language. First, it directs the Food and Drug Administration commissioner to provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designation and meet the voucher programme’s criteria. Breakthrough Therapy designation is a regulatory status for drugs that show preliminary clinical evidence of substantial improvement over existing therapies for a serious condition; it is not proof of effectiveness, and it does not guarantee approval. A priority voucher is intended to shorten review timelines, but the drug must still meet safety and efficacy standards. Second, it directs the FDA and the Drug Enforcement Administration to establish a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds, under the Right to Try Act, where basic safety requirements have been met.
Third, it directs the Department of Health and Human Services, through the Advanced Research Projects Agency for Health, to allocate at least 50 million dollars from existing funds to match state investments in psychedelic research programmes for serious mental illness. That is a direction to use existing funds for federal-state partnerships, not a new congressional appropriation, and the practical effect will depend on which states participate and what research they propose. Fourth, it directs HHS and the FDA to collaborate with the Department of Veterans Affairs and the private sector to increase clinical-trial participation, data sharing and real-world evidence generation. Fifth, it directs the Attorney General to initiate rescheduling reviews for products that successfully complete Phase 3 trials and receive FDA approval, so that rescheduling can follow approval promptly where appropriate. None of these steps, on its own, makes a psychedelic drug lawful to possess or prescribe outside a trial or an authorised pathway.
Within days, the FDA acted on the voucher provision. On April 24, 2026, the agency issued national priority vouchers for psilocybin programmes for depression and for methylone, a compound similar to MDMA, for post-traumatic stress disorder, and it permitted a sponsor to begin a Phase 1 study of noribogaine, a metabolite related to ibogaine, in a closely monitored setting in connection with alcohol use disorder. The FDA was careful to state that permission to begin a study does not mean a drug is approved or has been found safe or effective. That caution is standard regulatory language, but it is also the central caveat for the entire psychedelic push: accelerated review is not the same as established benefit, and early studies, however encouraging to participants, are not a substitute for large, controlled trials.
Ibogaine, veterans and the claims that need labelling
Ibogaine is the only compound singled out by name in the order, and it carries both the most powerful advocacy and the most serious safety questions. It is a Schedule I controlled substance in the United States, a category for substances with no currently accepted medical use and a high potential for abuse, a classification that dates to 1970. It has been used for decades in other settings, including clinics in Mexico, for substance-use disorders and trauma, and veterans who have travelled for treatment have told powerful personal stories of relief from post-traumatic stress, depression and addiction. Former Navy SEAL Marcus Luttrell, who underwent ibogaine therapy in Mexico, thanked Trump at the signing and said the order would save lives, a sentiment echoed by his twin brother, Representative Morgan Luttrell, who has also spoken about his own experience.
Those personal accounts are real to the people who tell them, and they help explain why the veteran angle has given the psychedelic cause political traction across party lines, including support from former Texas Governor Rick Perry and Texas legislators who funded ibogaine studies in 2025. But personal accounts are not clinical proof, and the efficacy figures sometimes quoted in connection with ibogaine should be treated strictly as claims, not as established findings. At the signing, Trump referred to a study suggesting an 80 to 90 percent reduction in symptoms of depression and anxiety within one month. That figure, as reported, appears to derive from small, uncontrolled work, and it has not been established by a large randomised trial. A Stanford study of 30 veterans with traumatic brain injury who received ibogaine combined with magnesium to reduce cardiac risk reported meaningful improvements in post-traumatic stress, anxiety and depression, but it had no placebo group, which limits what can be concluded about cause and effect.
The safety profile of ibogaine is also distinct from that of other psychedelics under study, and it deserves equal prominence. Ibogaine is linked to cardiac arrhythmias, and the medical literature has associated it with more than 30 deaths, according to the Multidisciplinary Association for Psychedelic Studies, a figure that reflects cases in varied settings, not a rate from a controlled trial. The FDA has historically been cautious about ibogaine research precisely because of cardiac concerns, which is why trial designs that include cardiac monitoring and magnesium, as in the Stanford work, are being watched closely. None of this means ibogaine cannot prove useful in a carefully controlled medical setting; it means that any future approval would need to show that benefits outweigh cardiac and other risks for a defined patient group, under defined monitoring, and that the treatment can be delivered safely at scale.
Psilocybin, MDMA and the wider field
The wider psychedelic field is further along in some respects than ibogaine, and that contrast is instructive. Psilocybin, the active compound in certain mushrooms, has Breakthrough Therapy designation for depression and is the subject of multiple clinical programmes. MDMA-assisted therapy for post-traumatic stress disorder was considered by an independent FDA advisory panel in 2024, which voted against its use at that time, a reminder that enthusiasm and evidence do not always move together. Methylone, for which a voucher was issued, is an MDMA-like compound being studied for post-traumatic stress disorder, but it too remains investigational. The order’s logic is to treat these programmes as a portfolio: accelerate the ones that have already met a threshold for priority review, generate more and better data, and let the regulatory process sort proven treatments from promising ideas.
Supporters argue that the current system is too slow for a crisis measured in suicides, and that priority review, federal-state research funding and Right to Try pathways are proportionate responses to a situation where people are already travelling abroad, paying 15,000 to 20,000 dollars per session at clinics in Mexico, and receiving treatment outside United States oversight. On that view, bringing research into the United States, under FDA supervision, is safer than leaving it offshore. Critics argue that the order’s rhetoric, including presidential praise for ibogaine and the speed of its development, risks creating public expectations that outrun the evidence, and that Right to Try pathways for Schedule I compounds raise difficult questions about who is eligible, who monitors safety, and who bears the cost. Both concerns can be true at once: research can be accelerated responsibly, and public communication can still overstate what has been proved.
The follow-through since April shows both momentum and limits. On August 18, 2026, Trump posted on Truth Social that Health Secretary Kennedy had received what he called a historic gift from the University of Miami, its original 1994 ibogaine Investigational New Drug application, which he said would give direct access to the foundational FDA authorisation to accelerate development as a medical treatment in the United States. He also pointed to what he described as incredible progress since April, including research funding, collaboration between Health and Human Services and Veterans Affairs, and FDA guidance. That post is a presidential claim about administrative progress, not an approval, and it should not be read as one. As of October 2026 reporting, no psychedelic drug covered by the order had received FDA approval as a treatment for serious mental illness, and ibogaine remained a Schedule I substance. The order therefore stands, months later, as a research and review acceleration programme whose clinical payoff is still unproven, however enthusiastic its supporters remain.
For patients and families, the practical takeaway is unglamorous but important. The order does not change the legal status of psychedelics for personal use, and possession remains a federal crime outside authorised research or treatment pathways. It does not mean insurance will cover a psychedelic treatment, or that a clinic in the United States can now offer ibogaine as a standard therapy. What it may change, over months and years, is the pace at which trials are run, the amount of federal-state research funding available, and the speed of FDA review for programmes that clear the evidence bar. That is a meaningful policy shift, but it is a shift in process, not a declaration that a cure has arrived. The next evidence to watch is not a speech or a social-media post, but trial results: larger, controlled studies, with cardiac and other safety data published and peer-reviewed, and FDA decisions that explain, in detail, what the data did and did not show.
Sources
USN reviewed reporting from multiple outlets for this story. Read more from The White House: https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/, Reason: https://reason.com/2026/07/05/trump-embraces-psychedelic-therapy/ and USA Today: https://www.usatoday.com/story/life/health-wellness/2026/08/18/trump-joe-rogan-praise-ibogaine-what-is-it/91355544007/.